5th Annual Inhalation & Respiratory Drug Delivery Congress

Discover novel case studies on the latest challenges and innovations in inhaled therapy formulation and device development, with in-depth presentations focusing on alternative therapeutic areas and advancements in combination products

Over 150 delegates from the inhalation, formulation and drug delivery industry representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic & research institutions.

Over 20 presentations and case studies focusing on the emerging therapies and key issues in inhalation and respiratory drug delivery as well as the latest developments in medical devices and digital health products.

View Agenda: https://bit.ly/35dZ8hc

Co-located with the 6th Annual Formulation & Drug Delivery Congress and Biomanufacturing Congress.

For more information contact e.hawkings@oxfordglobal.co.uk or visit the website: https://bit.ly/2KFgtrv

Go Social: Join our Formulation & Drug Delivery Network on LinkedIn, follow us on Twitter @FDDCongress & join the conversation at #FDDUK20

*2020 Live Webinar*

Inhaled Targeted-Inhibition Of Galectin-3 Dose Dependently Blocks Plasma Biomarkers In Patients With Idiopathic Pulmonary Fibros

Tue, Mar 3, 2020 2:00 PM - 3:00 PM GMT

Presented by Tariq Sethi, Co-Founder, Galacto Biotech and Former Chief Scientist Vice President Clinical Development Unit, AstraZeneca

Register (free): https://bit.ly/37NpwAv 

John Patton, President and Chief Executive Officer, Dance Pharmaceuticals

Mark Milton-Edwards, Head of Product & Health Solutions -Digital Health, Teva

Camilla Foged, Professor of Vaccine Design and Delivery, University of Copenhagen

Guilherme Safioti, Global Medical Director, Teva Digital Respiratory, Teva

Hlack Mohammed, Analytical Science & Technology Director, GlaxoSmithKline

Nico Ghilardi, Associate Director and Principal Scientist, Genentech

Michelle Dawson, Project Lead, GlaxoSmithKline